denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Symposia: ASH-a-Palooza
Program: Trainee Activities and Services
Friday, December 6, 2024: 1:30 PM-3:50 PM
Cafe Sevilla Restaurant
(Gaslamp Quarter)
Panelists:
Taxiarchis Kourelis, MD, Mayo Clinic
,
Miguel Angel Perales, MD, Memorial Sloan Kettering Cancer Center
,
Carlo Dufour, MD, Hematology Unit, IRCCS G. Gaslini Children's Hospital
,
Allen R. Chen, MD, Johns Hopkins Kimmel Cancer Center
,
Sarah M. Larson, MD, UCLA Health
,
Lori Muffly, MD, Stanford University School of Medicine
,
Ramzi Abboud, Washington University School of Medicine
and
Zachary D. Crees, MD, Washington University School of Medicine
Disclosures:
Kourelis: Pfizer: Research Funding; Novartis: Research Funding. Perales: Allogene: Consultancy, Research Funding; Adicet: Consultancy; Sellas: Other: DSMB member; OrcaBio: Consultancy, Current holder of stock options in a privately-held company; Syncopation: Consultancy; Novartis: Consultancy, Honoraria, Research Funding; Allovir: Consultancy; Astellas: Honoraria; VectivBio AG: Consultancy, Research Funding; Vor Biopharma: Consultancy; Omeros: Consultancy, Current equity holder in publicly-traded company; Merck: Consultancy, Research Funding; Caribou Biosciences: Consultancy; Celgene: Consultancy, Honoraria; AbbVie: Honoraria; Cidara Therapeutics: Other: DSMB member; Sanofi: Consultancy; Bristol-Myers Squibb: Consultancy, Honoraria; Miltenyi Biotec: Consultancy, Honoraria, Research Funding; Nektar Therapeutics: Consultancy, Honoraria, Research Funding; Incyte: Consultancy, Honoraria, Research Funding; Kite/Gilead: Consultancy, Honoraria, Research Funding; Karyopharm: Honoraria; MorphoSys: Honoraria; Takeda: Honoraria; Medigene: Other: DSMB member; Servier: Other: DSMB member. Dufour: Novartis: Consultancy; Sobi: Consultancy; Pfizer: Consultancy, Speakers Bureau; Gilead: Consultancy; Ono: Consultancy; Rockets: Consultancy. Larson: Regeneron: Other: Clinical trial; Sanofi: Other: Clinical trial; Ionis: Other: Clinical trial; Immpact bio: Other: Clinical trial; BMS: Other: Clinical trial; Pfizer: Other: Clinical trial; Janssen: Research Funding; Allogene: Other: Clinical trial; Bioline: Other: Clinical trial; TORL Biotherapeutics: Current holder of stock options in a privately-held company. Muffly: Autolus: Consultancy; Adaptive: Research Funding; Pfizer: Consultancy; Jasper: Research Funding; Bristol Myers Squibb: Consultancy; Wugen: Research Funding; Vor: Consultancy, Research Funding; Astellas: Consultancy; Cargo Therapeutics: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding. Crees: BioLineRx, Ltd.: Consultancy, Membership on an entity's Board of Directors or advisory committees.
Trainees have the opportunity to meet with leaders in the field. Trainees sign up for a one-on-one Blood Buddy ten-minute mentoring session with a faculty member. Blood Buddies are experts in various hematology topic areas. This is an excellent opportunity for trainees to network with and receive mentorship from seasoned faculty. There are 3 Blood Buddies sessions at the event. Although the speakers roles are marked as primary and alternate, multiple speakers may be asked to present on the same topic if that topic will be repeated in the following sets of Blood Buddies. The featured topics are: Adult Clinical Malignant Hematology; Pediatric Clinical Malignant Hematology; Adult Clinical Classical Hematology; Pediatric Clinical Classical Hematology; BMT Pediatric and Adult; Quality Improvement; Medical Education; PhD/Laboratory; Diversity, Equity, and Inclusion; International Medical Graduates; Future of Hematology (Artificial Intelligence); Industry Career Pathway; Federal Career Pathway.